Therapeutic Effects of Low Dose Acetylsalicylic Acid on Acute Central Serous Chorioretinopathy: A Prospective, Interventional, Single Centre Case Series

Objective: Central serous chorioretinopathy (CSCR) is a common cause of central vision loss, primarily affecting men 20–60 years of age. This study aimed to investigate the efficacy of low-dose aspirin for the treatment of acute CSCR. Methods: Totally 60 patients (60 eyes) with a history of acute CSC on fenofibrate were randomized into two groups: group A was treated with aspirin 100 mg per day orally for 1 month followed by 100 mg on alternate days for 5 months by evaluation of visual acuity, mean subretinal fluid vertical diameter (SFVD), Optical Coherence Tomography (OCT), and central macular thickness (CMT) at baseline and follow up period.  Group B received no medication and was considered as the control group. Follow-up times were the first week, 1, 2, 3 and 6 months after treatment initiation. Results: No differences were seen between the studied groups in terms of baseline BCVA (P = 0.968) and baseline SFVD (P = 0.774). BCVA improved, and SFVD was reduced significantly in the group A at all follow-up intervals compared with baseline values. Aspirin intervention (group A), compared with no intervention group (group B), was statistically more effective in improving BCVA (P < 0.001) and in reducing SFVD (P < 0.001) after 6 months. While 93.3% (n=28) of Group A’s cases had no recurrences during the follow-up period, only 60.0% (n=18) of patients in the group B had a resolution of CSCR with no recurrences. Conclusion: More rapid visual rehabilitation with fewer recurrences of CSCR were detected in the group A than in group B. These results demonstrated that orally administered aspirin may be a promising option for selected patients in the treatment of acute CSCR.

Therapeutic Effects of Low Dose Acetylsalicylic Acid on Acute Central Serous Chorioretinopathy: A Prospective, Interventional, Single Centre Case Series Keywords:

central serous chorioretinopathy , aspirin , acetyl salicylic acid , best corrected visual acuity (BCVA) , recurrence